HS-IT101
Cell therapy
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Non-Small Cell Lung Cancer · Phase 1Clear Cell Renal Cell Carcinoma · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07406724 NCT07406724 · Melanoma (Excluding Uveal Melanoma) Registry: NCT07406724 | 2 | PFS (1 year) 2027-12-31 | In progress: results expected 31 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Autologous tumor neoantigens (polyclonal, patient-specific) drugs
GC101. Compare all 2 Autologous tumor neoantigens (polyclonal, patient-specific) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Clear Cell Renal Cell Carcinoma: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HS-IT101: this drug | Phase 1 | Cell therapy | Autologous tumor neoantigens (polyclonal, patient-specific) | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | No reviewed efficacy summary in this indication | |
| Casdatifan | Phase 3 | Small molecule | HIF-2alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 2 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| Darlifarnib | Phase 1 | Small molecule | Farnesyltransferase | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb819 | Phase 1 | Multispecific antibody | ENPP3 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CTX131 | Discontinued | Cell therapy | CD70 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow HS-IT101 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.